Abstract

Lung cancer is the second most frequently diagnosed cancer and the leading cause of cancer-related mortality worldwide. Tumour ecosystems feature diverse immune cell types. Myeloid cells, in particular, are prevalent and have a well-established role in promoting the disease. In our study, we profile approximately 900,000 cells from 25 treatment-naive patients with adenocarcinoma and squamous-cell carcinoma by single-cell and spatial transcriptomics. We note an inverse relationship between anti-inflammatory macrophages and NK cells/T cells, and with reduced NK cell cytotoxicity within the tumour. While we observe a similar cell type composition in both adenocarcinoma and squamous-cell carcinoma, we detect significant differences in the co-expression of various immune checkpoint inhibitors. Moreover, we reveal evidence of a transcriptional “reprogramming” of macrophages in tumours, shifting them towards cholesterol export and adopting a foetal-like transcriptional signature which promotes iron efflux. Our multi-omic resource offers a high-resolution molecular map of tumour-associated macrophages, enhancing our understanding of their role within the tumour microenvironment.

Myeloid cell populations play a critical role in lung cancer progression. Here, the authors use scRNA-seq and spatial transcriptomics to identify changes in the phenotype of macrophages within the tumour microenvironment.

Details

Title
Single-cell and spatial transcriptomics analysis of non-small cell lung cancer
Author
De Zuani, Marco 1   VIAFID ORCID Logo  ; Xue, Haoliang 1   VIAFID ORCID Logo  ; Park, Jun Sung 2   VIAFID ORCID Logo  ; Dentro, Stefan C. 3 ; Seferbekova, Zaira 4   VIAFID ORCID Logo  ; Tessier, Julien 5 ; Curras-Alonso, Sandra 6 ; Hadjipanayis, Angela 5 ; Athanasiadis, Emmanouil I. 7   VIAFID ORCID Logo  ; Gerstung, Moritz 8 ; Bayraktar, Omer 9   VIAFID ORCID Logo  ; Cvejic, Ana 10   VIAFID ORCID Logo 

 Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); Wellcome Genome Campus, OpenTargets, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672); University of Cambridge, Department of Haematology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934); Wellcome Trust—Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK (GRID:grid.14105.31) (ISNI:0000000122478951) 
 Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); Wellcome Genome Campus, OpenTargets, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672); Wellcome Genome Campus, European Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672) 
 Wellcome Genome Campus, European Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672); DKFZ, Division of Artificial Intelligence in Oncology, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584) 
 Wellcome Genome Campus, European Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672) 
 Sanofi, Precision Medicine and Computational Biology, Cambridge, USA (GRID:grid.417555.7) (ISNI:0000 0000 8814 392X) 
 Sanofi, Precision Medicine and Computational Biology, Paris, France (GRID:grid.417924.d) 
 Wellcome Genome Campus, OpenTargets, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672); University of West Attica, Medical Image and Signal Processing Laboratory (MEDISP), Department of Biomedical Engineering, Athens, Greece (GRID:grid.499377.7) (ISNI:0000 0004 7222 9074) 
 Wellcome Genome Campus, OpenTargets, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672); Wellcome Genome Campus, European Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672); DKFZ, Division of Artificial Intelligence in Oncology, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584) 
 Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); Wellcome Genome Campus, OpenTargets, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672) 
10  Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); Wellcome Genome Campus, OpenTargets, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672); University of Cambridge, Department of Haematology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934); University of Copenhagen, Biotech Research & Innovation Centre (BRIC), Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X) 
Pages
4388
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3059116429
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.